FindTrial
Sign In

CONTINOUS INFUSION OF 5-FLUORURACIL PLUS OCTREOTIDE LONG ACTING IN PATIENTS WITH NEUROENDOCRINE ADVANCED NOT SMALL CELL TUMORS

CONTINOUS INFUSION OF 5-FLUORURACIL PLUS OCTREOTIDE LONG ACTING IN PATIENTS WITH NEUROENDOCRINE ADVANCED NOT SMALL CELL TUMORS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-003963-58-IT
Enrollment
Unknown
Registered
2007-08-10
Start date
2005-03-07
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TREATMENT OF PATIENTS WITH NON SMALL CELL NEUROENDOCRINE TUMORS WITH LOW PROLIFERATIVE ACTIVITY WITHOUT SURGICAL APPROACH Level: PT Classification code 10057270

Interventions

Trade Name: SANDOSTATINA LAR*IM FL 20MG+2F Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Octreotide CAS Number: 83150-76-9 Concentration unit: mg milligram(s)

Sponsors

AZIENDA OSPEDALIERA S. LUIGI GONZAGA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026